Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia-Reference-Cited by-同舟云学术

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

Published:2015-05-07 Issue:19 Volume:125 Page:2985-2994
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kühnl Andrea¹²,Valk Peter J. M.³,Sanders Mathijs A.³,Ivey Adam¹,Hills Robert K.⁴,Mills Ken I.⁵,Gale Rosemary E.⁶,Kaiser Martin F.²,Dillon Richard¹,Joannides Melanie¹,Gilkes Amanda⁴,Haferlach Torsten⁷,Schnittger Susanne⁷,Duprez Estelle⁸,Linch David C.⁶,Delwel Ruud³,Löwenberg Bob³,Baldus Claudia D.²,Solomon Ellen¹,Burnett Alan K.⁴,Grimwade David¹

Affiliation:

1. Department of Medical and Molecular Genetics, King’s College London, Faculty of Life Sciences and Medicine, London, United Kingdom;

2. Department of Hematology and Oncology, Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany;

3. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;

4. Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;

5. Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom;

6. Department of Haematology, University College London, London, United Kingdom;

7. MLL Munich Leukemia Laboratory, Munich, Germany; and

8. Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique UMR7258, Institut Paoli-Calmettes, Aix Marseille University, Marseille, France

Abstract

Key Points CXXC5 inhibits Wnt signaling and is a candidate tumor suppressor in AML. Low CXXC5 expression is an independent prognostic factor in AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/19/2985/1385005/2985.pdf

Reference50 articles.

1. Therapeutic advances in acute myeloid leukemia.;Burnett;J Clin Oncol,2011

2. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.;Burnett;Br J Haematol,2009

3. The CXXC finger 5 protein is required for DNA damage-induced p53 activation.;Zhang;Sci China C Life Sci,2009